TW200501952A - Pirfenidone gel formulations - Google Patents
Pirfenidone gel formulationsInfo
- Publication number
- TW200501952A TW200501952A TW093104281A TW93104281A TW200501952A TW 200501952 A TW200501952 A TW 200501952A TW 093104281 A TW093104281 A TW 093104281A TW 93104281 A TW93104281 A TW 93104281A TW 200501952 A TW200501952 A TW 200501952A
- Authority
- TW
- Taiwan
- Prior art keywords
- gel formulations
- pirfenidone
- formulations
- pheny1
- methy1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
New gel formulations for treating fibrotic diseases are provided. The invention relates to gel formulations which comprise 5-methy1-1-pheny1-2-(1H)-pyridone, or a pharmaceutically acceptable salt or ester thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003045110 | 2003-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200501952A true TW200501952A (en) | 2005-01-16 |
Family
ID=32905481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093104281A TW200501952A (en) | 2003-02-21 | 2004-02-20 | Pirfenidone gel formulations |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW200501952A (en) |
WO (1) | WO2004073713A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5248040B2 (en) * | 2007-05-25 | 2013-07-31 | リードケミカル株式会社 | Patch containing 5-methyl-1-phenyl-2- (1H) -pyridone |
MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
JP2010120912A (en) * | 2008-11-21 | 2010-06-03 | Lead Chemical Co Ltd | Adhesive skin patch containing 5-methyl-1-phenyl-2-(1h)-pyridone |
US20110313004A1 (en) | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
MX346763B (en) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne. |
MX356551B (en) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne. |
MX366086B (en) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02215719A (en) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion |
JP2610052B2 (en) * | 1989-11-07 | 1997-05-14 | 信越化学工業株式会社 | External gel base |
CA2161648A1 (en) * | 1993-05-07 | 1994-11-24 | Solomon B. Margolin | Compositions and methods for reparation and prevention of fibrotic lesions |
EP1113798B1 (en) * | 1998-09-18 | 2003-01-02 | Mepha AG | Topical formulation of alkyl-, phenyl-pyridone |
-
2004
- 2004-02-20 WO PCT/JP2004/001968 patent/WO2004073713A1/en not_active Application Discontinuation
- 2004-02-20 TW TW093104281A patent/TW200501952A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004073713A1 (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1790638A4 (en) | Carbamoylpyridone derivative having hiv integrase inhibitory activity | |
LTC1830843I2 (en) | Indolidone derivatives for the treatment or prevention of fibrotic diseases | |
WO2005065645A3 (en) | Donepezil formulations | |
LU92761I2 (en) | N-(5-hydroxy-2,4-diert-butyl-phenyl)-4oxo-1h-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof | |
AU2002950217A0 (en) | 8- Hydroxy Quinoline Derivatives | |
WO2005046603A3 (en) | Pyridine compounds | |
ZA200609899B (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
MY145795A (en) | Pyrazoline compounds | |
DK1814848T3 (en) | 2,3,4-substituted-cyclopentanones as therapeutic agents | |
WO2006001866A3 (en) | Crystalline forms of n-desmethylclozapine | |
AP2005003451A0 (en) | HIV integrase inhibitors. | |
HK1092180A1 (en) | Methods for treating ischemic diseases | |
AU2003258145A8 (en) | Substituted phenylindoles for the treatment of hiv | |
TW200501952A (en) | Pirfenidone gel formulations | |
AU2003244181A1 (en) | Phenoxypyridine derivative or salt thereof | |
WO2005007642A3 (en) | Novel azaheterocyclic amides useful for treating pain | |
AU2003223780A1 (en) | Treatment for pompe disease | |
DE602005015323D1 (en) | prostaglandin | |
HK1080768A1 (en) | Use of epothilone derivatives for the treatment ofhyperparathyroidism | |
AU2003269985A1 (en) | Methods for increasing the rate of heart muscle contraction | |
ZA200407358B (en) | Microorganism for genetic therapeutic treatment ofproliferative diseases. | |
MX2007002532A (en) | Methods of treating proliferative skin diseases using carbazole derivatives. | |
TW200514557A (en) | Pharmaceutically acceptable salt of amlodipine and method of preparing the same |